MOTIVATION: The growth of next-generation sequencing (NGS) has not only dramatically accelerated the pace of research in the field of genomics, but it has also opened the door to personalized medicine and diagnostics. The resulting flood of data has led to the rapid development of large numbers of bioinformatic tools for data analysis, creating a challenging situation for researchers when choosing and configuring a variety of software for their analysis, and for other researchers trying to replicate their analysis. As NGS technology continues to expand from the research environment into clinical laboratories, the challenges associated with data analysis have the potential to slow the adoption of this technology. RESULTS: Here we discuss the potential of virtual machines (VMs) to be used as a method for sharing entire installations of NGS software (bioinformatic 'pipelines'). VMs are created by programs designed to allow multiple operating systems to co-exist on a single physical machine, and they can be made following the object-oriented paradigm of encapsulating data and methods together. This allows NGS data to be distributed within a VM, along with the pre-configured software for its analysis. Although VMs have historically suffered from poor performance relative to native operating systems, we present benchmarking results demonstrating that this reduced performance can now be minimized. We further discuss the many potential benefits of VMs as a solution for NGS analysis and describe several published examples. Lastly, we consider the benefits of VMs in facilitating the introduction of NGS technology into the clinical environment. CONTACT: brian.wilhelm@umontreal.ca.
MOTIVATION: The growth of next-generation sequencing (NGS) has not only dramatically accelerated the pace of research in the field of genomics, but it has also opened the door to personalized medicine and diagnostics. The resulting flood of data has led to the rapid development of large numbers of bioinformatic tools for data analysis, creating a challenging situation for researchers when choosing and configuring a variety of software for their analysis, and for other researchers trying to replicate their analysis. As NGS technology continues to expand from the research environment into clinical laboratories, the challenges associated with data analysis have the potential to slow the adoption of this technology. RESULTS: Here we discuss the potential of virtual machines (VMs) to be used as a method for sharing entire installations of NGS software (bioinformatic 'pipelines'). VMs are created by programs designed to allow multiple operating systems to co-exist on a single physical machine, and they can be made following the object-oriented paradigm of encapsulating data and methods together. This allows NGS data to be distributed within a VM, along with the pre-configured software for its analysis. Although VMs have historically suffered from poor performance relative to native operating systems, we present benchmarking results demonstrating that this reduced performance can now be minimized. We further discuss the many potential benefits of VMs as a solution for NGS analysis and describe several published examples. Lastly, we consider the benefits of VMs in facilitating the introduction of NGS technology into the clinical environment. CONTACT: brian.wilhelm@umontreal.ca.
Authors: Kathleen M Fisch; Tobias Meißner; Louis Gioia; Jean-Christophe Ducom; Tristan M Carland; Salvatore Loguercio; Andrew I Su Journal: Bioinformatics Date: 2015-01-30 Impact factor: 6.937
Authors: Jason Li; Maria A Doyle; Isaam Saeed; Stephen Q Wong; Victoria Mar; David L Goode; Franco Caramia; Ken Doig; Georgina L Ryland; Ella R Thompson; Sally M Hunter; Saman K Halgamuge; Jason Ellul; Alexander Dobrovic; Ian G Campbell; Anthony T Papenfuss; Grant A McArthur; Richard W Tothill Journal: PLoS One Date: 2014-04-21 Impact factor: 3.240
Authors: Hao Lu; Thomas G Papathomas; David van Zessen; Ivo Palli; Ronald R de Krijger; Peter J van der Spek; Winand N M Dinjens; Andrew P Stubbs Journal: Diagn Pathol Date: 2014-11-25 Impact factor: 2.644
Authors: Randolph S Faustino; D Kent Arrell; Clifford D L Folmes; Andre Terzic; Carmen Perez-Terzic Journal: Croat Med J Date: 2013-08 Impact factor: 1.351
Authors: Bruce Budowle; Nancy D Connell; Anna Bielecka-Oder; Rita R Colwell; Cindi R Corbett; Jacqueline Fletcher; Mats Forsman; Dana R Kadavy; Alemka Markotic; Stephen A Morse; Randall S Murch; Antti Sajantila; Sarah E Schmedes; Krista L Ternus; Stephen D Turner; Samuel Minot Journal: Investig Genet Date: 2014-07-30